Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
I originally invested in NSCI because of Glycotest which, if successful will be real money maker. In the annual report they have given a lot more detail about it's current status.
Vortex bio also has great potential, just look at AGL!
Wilco, Below are a couple of examples that I have seen which give you a feel for the scope.
https://www.pbctoday.co.uk/news/planning-construction-news/social-housing-disruptors-framework/105366/
https://www.housing-technology.com/q-bot-underfloor-robots-at-plus-dane/
From what I have seen, at the beginning Q-bot was mainly doing private one off household type jobs. Now they involved in framework agreements, housing authorities etc.
https://www.biospace.com/article/circulating-tumor-cells-market-size-to-surpass-us-20-3-bn-by-2030/
"Advancements in technologies such as immunofluorescence, NGS, FISH, and qPCR are anticipated to drive the clinical utility of these cells, and thus accelerating revenue growth for CTC analyses. Several companies are investing in the development of products that help in CTC analysis and downstream assays. For instance, Vortex Biosciences offers various CTC analysis products, including immunofluorescence, cytopathology, cytogenetics (FISH), cell culture, and genomics."
https://www.investorschronicle.co.uk/ideas/2022/05/13/a-ben-graham-value-buy/
In the interim 2021 report NSCI had revenue of £400k which should be growing with via proaxsis (launch of new products) and with increasing managed services.
Besides the investments NSCI is a revenue generating business.